Prelude Therapeutics (PRLD) Competitors $0.93 +0.02 (+2.65%) As of 08/14/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRLD vs. TVGN, CRBU, CYBN, OGI, DMAC, CRDF, RAPT, LYEL, ACRS, and SLSShould you be buying Prelude Therapeutics stock or one of its competitors? The main competitors of Prelude Therapeutics include Semper Paratus Acquisition (TVGN), Caribou Biosciences (CRBU), Cybin (CYBN), Organigram Global (OGI), DiaMedica Therapeutics (DMAC), Cardiff Oncology (CRDF), Rapt Therapeutics (RAPT), Lyell Immunopharma (LYEL), Aclaris Therapeutics (ACRS), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry. Prelude Therapeutics vs. Its Competitors Semper Paratus Acquisition Caribou Biosciences Cybin Organigram Global DiaMedica Therapeutics Cardiff Oncology Rapt Therapeutics Lyell Immunopharma Aclaris Therapeutics SELLAS Life Sciences Group Prelude Therapeutics (NASDAQ:PRLD) and Semper Paratus Acquisition (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk. Do insiders & institutionals have more ownership in PRLD or TVGN? 79.7% of Prelude Therapeutics shares are owned by institutional investors. 63.9% of Prelude Therapeutics shares are owned by insiders. Comparatively, 73.2% of Semper Paratus Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media favor PRLD or TVGN? In the previous week, Semper Paratus Acquisition had 2 more articles in the media than Prelude Therapeutics. MarketBeat recorded 8 mentions for Semper Paratus Acquisition and 6 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 0.40 beat Semper Paratus Acquisition's score of 0.23 indicating that Prelude Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Semper Paratus Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, PRLD or TVGN? Prelude Therapeutics has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Semper Paratus Acquisition has a beta of -0.77, meaning that its share price is 177% less volatile than the S&P 500. Do analysts rate PRLD or TVGN? Prelude Therapeutics presently has a consensus price target of $4.50, suggesting a potential upside of 376.19%. Semper Paratus Acquisition has a consensus price target of $10.00, suggesting a potential upside of 920.41%. Given Semper Paratus Acquisition's higher probable upside, analysts plainly believe Semper Paratus Acquisition is more favorable than Prelude Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prelude Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Semper Paratus Acquisition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PRLD or TVGN more profitable? Semper Paratus Acquisition's return on equity of 0.00% beat Prelude Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Prelude TherapeuticsN/A -89.18% -69.26% Semper Paratus Acquisition N/A N/A -934.56% Which has preferable earnings & valuation, PRLD or TVGN? Semper Paratus Acquisition has lower revenue, but higher earnings than Prelude Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrelude Therapeutics$7M7.62-$127.17M-$1.69-0.56Semper Paratus AcquisitionN/AN/A-$13.73MN/AN/A SummaryPrelude Therapeutics beats Semper Paratus Acquisition on 6 of the 11 factors compared between the two stocks. Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRLD vs. The Competition Export to ExcelMetricPrelude TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.21M$2.48B$5.62B$9.84BDividend YieldN/A1.76%4.61%4.07%P/E Ratio-0.5622.0530.2925.74Price / Sales7.62742.42463.41115.83Price / CashN/A184.4138.2159.48Price / Book0.404.838.826.15Net Income-$127.17M$31.61M$3.25B$265.06M7 Day Performance10.20%4.55%3.71%2.60%1 Month Performance15.97%5.69%5.85%2.83%1 Year Performance-83.62%12.71%29.92%25.58% Prelude Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRLDPrelude Therapeutics3.0529 of 5 stars$0.95+4.2%$4.50+376.2%-81.7%$51.21M$7M-0.56120News CoverageEarnings ReportTVGNSemper Paratus Acquisition3.7486 of 5 stars$0.99-0.7%$10.00+907.5%+35.2%$183.88MN/A0.003CRBUCaribou Biosciences2.8222 of 5 stars$2.10+7.7%$8.50+304.8%+5.3%$181.36M$9.99M0.00100News CoverageEarnings ReportAnalyst RevisionGap UpCYBNCybin2.6131 of 5 stars$7.68+1.6%$85.00+1,006.8%N/A$181.17MN/A-1.7550News CoveragePositive NewsOGIOrganigram Global0.606 of 5 stars$1.38+3.8%N/A-17.9%$178.26M$117.47M0.00860News CoverageEarnings ReportGap DownDMACDiaMedica Therapeutics1.7678 of 5 stars$4.36+5.8%$10.75+146.6%+72.7%$176.68MN/A0.0020News CoverageEarnings ReportShort Interest ↑CRDFCardiff Oncology2.0472 of 5 stars$2.51-4.9%$11.70+366.1%+11.9%$175.63M$680K0.0020RAPTRapt Therapeutics4.5879 of 5 stars$10.76+2.6%$20.57+91.2%-34.3%$173.46M$1.53M0.0080Earnings ReportAnalyst ForecastAnalyst RevisionLYELLyell Immunopharma3.3013 of 5 stars$11.37+3.2%$15.00+31.9%-55.2%$170.34M$60K0.00270Trending NewsEarnings ReportGap DownACRSAclaris Therapeutics2.6239 of 5 stars$1.56+2.0%$8.71+458.6%+44.4%$165.67M$18.72M0.00100Earnings ReportSLSSELLAS Life Sciences Group2.8757 of 5 stars$1.59-4.2%$7.00+340.3%+29.2%$165.63M$1M0.0010News CoverageEarnings Report Related Companies and Tools Related Companies Semper Paratus Acquisition Alternatives Caribou Biosciences Alternatives Cybin Alternatives Organigram Global Alternatives DiaMedica Therapeutics Alternatives Cardiff Oncology Alternatives Rapt Therapeutics Alternatives Lyell Immunopharma Alternatives Aclaris Therapeutics Alternatives SELLAS Life Sciences Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRLD) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access